ENG and cancer: Importantly, both endoglin and ALK1 are emerging as successful targets for cancer therapies in the general population: The use of a soluble chimeric protein (ALK1-Fc), an inhibitor of ALK-1, has been shown to result in significant tumour-suppression both in vitro and in vivo [53].